AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00326820
Drug: Zolendronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
Trial: NCT00312520
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01307423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03736044
Drug: TNF-blockers suspension in patients with rheumatoid arthritis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
Trial: NCT00942006
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg bid, 14 days
Trial: NCT02213718
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
Trial: NCT01497392
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02687269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Placebo twice daily in the three days before surgery
Trial: NCT04438421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Trial: NCT02053974
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone
Trial: NCT01794780
Drug: theophylline based treatment
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: theophylline based treatment
Trial: NCT01794780
Drug: Other treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments
Trial: NCT01400737
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
Trial: NCT01400737
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
Trial: NCT03567655
Drug: Farlutal tab. 500mg/ Pfizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone Acetate
Trial: NCT01874483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01772134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Powder, Placebo
Trial: NCT00138840
Drug: STA-5326 mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02721862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
Trial: NCT01440101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00763893
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
Trial: NCT02279511
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 500 mL of saline solution. (IV)
Trial: NCT01982630
Drug: MK-8521
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01982630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04396587
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil(0.1μg/kg) was administered before anesthesia induction.
Trial: NCT04396587
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 10ml
Trial: NCT00160927
Drug: actylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04439786
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the control group will be given the same volume of saline.
Trial: NCT02441530
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00303810
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00303810
Drug: high-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00303810
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00448461
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison between heparin and bivalirudin
Trial: NCT02725502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
Trial: NCT00761215
Drug: TR-701 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral TR-701 200 mg for 5 to 7 days
Trial: NCT00761215
Drug: TR-701 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral TR-701 300 mg for 5 to 7 days
Trial: NCT00761215
Drug: TR-701 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR-701 400 mg for 5 to 7 days
Trial: NCT02885181
Drug: GS-9876 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered orally once daily
Trial: NCT03486730
Drug: BT1718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
Trial: NCT02885181
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Background therapy with methotrexate administered orally or parenterally once weekly
Trial: NCT00513279
Drug: GSK618334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
Trial: NCT02280811
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
Trial: NCT03443024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution administered subcutaneously.
Trial: NCT05368675
Drug: medication for opioid use disorder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
Trial: NCT01201499
Drug: Continuous IV remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
Trial: NCT01645761
Drug: Endonase
RxNorm normalized name: INCONTINENCE DEVICE MALE C3 LARGE ENDOCARE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI- based triple therapy with endonase
Trial: NCT04232449
Drug: PREDNISON Galepharm Tabl. 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
Trial: NCT04232449
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 daily- doses of placebo (2 tablets)
Trial: NCT00004829
Drug: tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03949673
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Trial: NCT03949673
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Trial: NCT03949673
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Trial: NCT03949673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Trial: NCT00033735
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
Trial: NCT04244825
Drug: Control: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 150 mg capsules '00' size (PO) BID
Trial: NCT01568216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT01938859
Drug: Shuganjieyu capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
Trial: NCT00513279
Drug: GSK618334 matching placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
Trial: NCT04237649
Drug: KAZ954
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAZ954 will be administered in every arm.
Trial: NCT03560362
Drug: Bupivacaine / Epinephrine
RxNorm normalized name: bupivacaine / epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01501487
Drug: PTH followed by dose dense AC of FEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel.
Trial: NCT01295333
Drug: The initiation of LT4 as soon as the first biological signs of hypothyroidism.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02079727
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02079727
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04700267
Drug: GLPG3970 film-coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3970 for oral administration
Trial: NCT03095092
Drug: BIA 6-512 400 mg
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
Trial: NCT01779609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00187083
Drug: E. coli Asparaginase, PEG-L-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for details of treatment interventions.
Trial: NCT00892437
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
Trial: NCT00892437
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Trial: NCT00892437
Drug: COBI placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match COBI administered orally once daily
Trial: NCT00892437
Drug: RTV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match RTV administered orally once daily
Trial: NCT04017403
Drug: Bifidobacterium triple live capsule
RxNorm normalized name: Bifidobacterium infantis Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
Trial: NCT04017403
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos were administrated as same as the bifidobacterium live capsule
Trial: NCT03185130
Drug: Normal Saline 20mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
Trial: NCT03431610
Drug: SB414 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT03431610
Drug: SB414 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT03431610
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01591980
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo capsules will be administered in the same way.
Trial: NCT02750410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00327392
Drug: AQUAVAN® (fospropofol disodium) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01894516
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0634 capsules.
Trial: NCT01894516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules.
Trial: NCT00278525
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care medication will be given
Trial: NCT02886715
Drug: Tazorac®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
Trial: NCT02886715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
Trial: NCT00356915
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
Trial: NCT03932240
Drug: Cryoprecipitate
RxNorm normalized name: Cryoprecipitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
Trial: NCT00294125
Drug: Flavocoxid
RxNorm normalized name: Flavocoxid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily flavocoxid for 12 weeks
Trial: NCT00294125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo for 12 weeks
Trial: NCT01152853
Drug: PF00299804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
Trial: NCT02371629
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
Trial: NCT02371629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to NVA237
Trial: NCT01330290
Drug: Neupro®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
Trial: NCT00824421
Drug: UK-453, 061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
Trial: NCT02298101
Drug: Technetium-99m - Diethylenetriaminepentaacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution placed on the nebulizer reservoir
Trial: NCT02201940
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily
Trial: NCT02201940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT04391764
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
Trial: NCT03982225
Drug: Polyene phosphatidylcholine injection
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
Trial: NCT03982225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT02354950
Drug: GSK1265744 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
Trial: NCT03844438
Drug: LPM3480226
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.